OPT
- Opthea Limited
()
Overview
Company Summary
Opthea Limited (OPT) is a biotechnology company that specializes in the development and commercialization of therapies for the treatment of various eye diseases. The company focuses on targeting the underlying causes of eye diseases and designing novel therapeutics to improve visual outcomes for patients.
Opthea is primarily centered around developing drugs for the treatment of wet age-related macular degeneration (wet AMD), a chronic eye disease that can lead to severe vision loss. Wet AMD is characterized by the abnormal growth of blood vessels in the retina, causing fluid leakage and damage to the central vision.
The company's lead product candidate, OPT-302, is a novel VEGF-C/D inhibitor designed to block the abnormal blood vessel formation associated with wet AMD. By inhibiting the VEGF-C and VEGF-D proteins, OPT-302 aims to reduce the leakage and improve the overall health of the retina, ultimately preserving and restoring vision in patients.
Opthea has conducted several clinical trials to evaluate the safety and efficacy of OPT-302 as both a monotherapy and in combination with anti-VEGF-A therapies. The results from these trials have shown promising results, with OPT-302 demonstrating the potential to provide additional benefits over the standard of care treatments for wet AMD.
In addition to its work in wet AMD, Opthea is also exploring the potential of its drug candidates for the treatment of other eye diseases, including diabetic macular edema and diabetic retinopathy.
Overall, Opthea Limited is a biotechnology company dedicated to advancing innovative therapies to address significant unmet medical needs in the field of ophthalmology, with a specific focus on the treatment of wet AMD and other related eye conditions.